TD Cowen analyst Yaron Werber has maintained their bullish stance on EXEL stock, giving a Buy rating on January 27.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Yaron Werber has given his Buy rating due to a combination of factors contributing to Exelixis’s promising outlook. One key reason is the solid financial performance in the recent quarter, where Exelixis reported revenues beating both company and consensus estimates, driven by a notable increase in sales of their lead drug, cabo. This, combined with the company’s guidance for fiscal year 2025, suggests robust revenue growth potential.
Furthermore, Werber sees significant potential in Exelixis’s pipeline, particularly with the anticipated launch of cabo for NET and the promising late-stage trials of zanzalintinib. The upcoming data releases for multiple cancer indications in 2025 are viewed as potential catalysts that could significantly enhance the company’s market position. Werber also appreciates the company’s reasonable stock valuation in light of the positive risk/reward profile presented by their diverse and advancing pipeline.
Werber covers the Healthcare sector, focusing on stocks such as Amgen, Exelixis, and Genmab. According to TipRanks, Werber has an average return of 8.4% and a 50.54% success rate on recommended stocks.
In another report released on January 27, Truist Financial also maintained a Buy rating on the stock with a $43.00 price target.